CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), rejoins the show to discuss recent additions to the board of directors, Pro 140's impact on cancer treatment, and plans for 2019.

Colon Cancer # humanized monoclonal antibodies # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV # Pro140 # leronlimap